Study of the Sars-Cov2 Neuroinvasiveness - COVID19 (CORONEVRAXE)

Fondation Ophtalmologique Adolphe de Rothschild

Status: Terminated

Conditions: COVID19

Treatments: Drug: Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies

Study type: Interventional

Funder types: NETWORK

Identifiers

NCT04427254

PBN_2020_16

Details and patient eligibility

About

Sars-Cov2 (COVID-19) may invade the CNS inducing neurological diseases such as anosmia, ageusia, encephalitis, ischemic or hemorrhagic stroke. Management of severe neurological complications in COVID-19 patients may require ventricular cerebrospinal fluid drainage and cranial decompression. During surgery, cerebrospinal fluid, meninges and brain parenchyma can be safely removed from the patient. In this study, COVID-19 patients will be evaluated first, for the presence of Sars-Cov2 in the cerebrospinal fluid and/or biopsies and second, for the consequences of Sars-Cov2 neuroinfection in terms of inflammatory and immune responses.

Enrollment: 2 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• COVID-19 patients requiring an external ventricular drain, a decompressive craniectomy or an intracranial hematoma surgery

Exclusion criteria

• Pregnant or lactating women

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

2 participants in 1 patient group

Neurological biological samples

Experimental group

Treatment:

Drug: Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies